GSK Just Dropped $10.6 Billion on a Lung Cancer Bet
Key takeaways
- Tell us how you invest and we ll show you why it s our #1 pick.
- British pharma giant GSK plc has entered into a definitive agreement to acquire Boston-based clinical-stage biopharmaceutical specialist Nuvalent, Inc. for $10.6 billion in cash.
- The deal includes three product lines headlined by two late-stage, potentially best-in-class tyrosine kinase inhibitors under priority review by the U.S.
GSK Just Dropped $10.6 Billion on a Lung Cancer Bet Mark Nichols Tue, June 9, 2026 at 10:29 PM GMT+7 4 min read GSK NVDA NUVL GSK Just Dropped $10.6 Billion on a Lung Cancer Bet - Moby THE GIST Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we ll show you why it s our #1 pick. Tap here.
British pharma giant GSK plc has entered into a definitive agreement to acquire Boston-based clinical-stage biopharmaceutical specialist Nuvalent, Inc. for $10.6 billion in cash. The transaction stands as the second-largest biopharma takeover of the year, providing GSK with an immediate, high-value footprint in the targeted non-small cell lung cancer market.
The deal includes three product lines headlined by two late-stage, potentially best-in-class tyrosine kinase inhibitors under priority review by the U.S. Food and Drug Administration, with regulatory approval rulings slated before the end of the year.